1. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline. (28th August 2018) Authors: Fitchett, D; Inzucchi, S E; Cannon, C P; McGuire, D K; Johansen, O E; Sambevski, S; Hehnke, U; George, J; Zinman, B Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial. (28th August 2018) Authors: McGuire, D K; Zinman, B; Inzucchi, S E; Anker, S D; Wanner, C; Kaspers, S; George, J T; Elsasser, U; Woerle, H J; Lund, S S; Fitchett, D Journal: European heart journal Issue: Volume 39(2018)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗